Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

Erstellt von NightTrain 

Fate Therapeutics Inc. diskutieren

Fate Therapeutics Inc.

WKN: A1W50M / Symbol: FATE / Name: Fate / Aktie / Biotechnologie & medizinische Forschung / Small Cap /

4,02 €
-5,51 %

Buy Fate Therapeutics Inc.

Einschätzung Buy
Rendite (%) 26,81 %
Kursziel 9,37
Veränderung
Endet am 01.03.24

Fate Therapeutics, Inc. (NASDAQ: FATE) had its "buy" rating re-affirmed by analysts at EF Hutton Acquisition Co. I. They now have a $10.00 price target on the stock.
Ratings data for FATE provided by MarketBeat

Fate Therapeutics, Inc. (NASDAQ: FATE) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Ratings data for FATE provided by MarketBeat

Einschätzung Buy
Rendite (%) 69,53 %
Kursziel 7,31
Veränderung
Endet am 20.11.24

Fate Therapeutics, Inc. (NASDAQ: FATE) had its price target lowered by analysts at Mizuho from $12.00 to $8.00. They now have a "buy" rating on the stock.
Ratings data for FATE provided by MarketBeat

Einschätzung Buy
Rendite (%) -37,32 %
Kursziel 9,22
Veränderung
Endet am 27.02.25

Fate Therapeutics, Inc. (NASDAQ: FATE) had its price target raised by analysts at Barclays PLC from $6.00 to $10.00. They now have an "overweight" rating on the stock.
Ratings data for FATE provided by MarketBeat

Einschätzung Sell
Rendite (%) -40,84 %
Kursziel 5,56
Veränderung
Endet am 28.03.25

Fate Therapeutics, Inc. (NASDAQ: FATE) had its price target raised by analysts at Bank of America Co. from $2.00 to $6.00. They now have an "underperform" rating on the stock.
Ratings data for FATE provided by MarketBeat